Form 4: SOPHiA GENETICS Exec Sells Shares Under 10b5-1 Plan

Jurgi Camblong, Executive Chairman and Director of SOPHiA GENETICS SA, executed a Rule 10b5-1 trading plan, resulting in the sale of ordinary shares and the exercise of stock options.

Summary

• Jurgi Camblong, Executive Chairman and Director of SOPHiA GENETICS SA, engaged in transactions involving the company's ordinary shares and stock options.
• These transactions were conducted under a pre-arranged trading plan designed to comply with Rule 10b5-1(c) of the Securities Exchange Act of 1934.
• On June 29, 2026, Camblong acquired 18,060 ordinary shares at $3.16 per share and subsequently sold 18,060 shares at a weighted average price of $5.867, with individual sales ranging from $5.867 to $6.00.
• On June 30, 2026, Camblong acquired an additional 45,419 ordinary shares at $3.16 per share and sold these shares at a weighted average price of $6.1439, with individual sales ranging from $6.10 to $6.30.
• Further sales on June 30, 2026, included 19,650 shares at a weighted average price of $6.0215 (ranging from $6.00 to $6.03) and 200 shares at $6.30.
• Following these transactions, Camblong's beneficial ownership of ordinary shares directly held is 3,581,293.
• The filing also indicates the exercise of stock options, with 18,060 options exercised on June 29, 2026, and 45,419 options exercised on June 30, 2026, both at an exercise price of $3.16.
• After these option exercises, Camblong holds an aggregate of 4,646,057 derivative stock options across various grant tranches.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the significant sale of shares by a key executive, despite the use of a 10b5-1 plan. While the plan itself is a positive governance practice, the volume of shares sold can raise concerns among investors.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating a structured and pre-planned approach to stock sales, which can mitigate concerns about insider trading.
• The exercise of stock options at $3.16 and subsequent sale of shares at significantly higher prices ($5.867 to $6.30) suggests a profitable outcome for the executive on these specific option grants.

Negatives

• A significant number of ordinary shares were sold by a key executive, which could be interpreted negatively by the market, despite being part of a trading plan.
• The sale of 18,060 shares on June 29 and 45,419 shares on June 30, along with smaller sales, represents a notable divestment of holdings by the Executive Chairman.

Risks

• The sale of a substantial number of shares by a high-ranking executive, even under a 10b5-1 plan, may signal a lack of confidence in future stock performance or a need for personal liquidity, potentially impacting investor sentiment.
• The weighted average sale prices indicate a range of selling prices, suggesting that not all shares were sold at the highest possible price within the reported range, though this is typical for large block trades.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. It solely reports on past transactions executed by an insider.

Management Comments

• The transactions were made pursuant to a duly adopted trading plan under Rule 10b5-1(c).
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the range set forth in the footnotes upon written request.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing insider transactions are common in the biotechnology and healthcare technology sectors. The use of Rule 10b5-1 plans is a standard practice for executives to manage their stock holdings while adhering to insider trading regulations, especially during periods of stock price volatility or personal financial planning.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the sale of shares by a key executive with some concern, potentially impacting short-term stock sentiment, even though it's under a pre-planned trading strategy.
• Employees: The stock option exercises by the executive could be seen as a positive indicator of the value of equity compensation, but the subsequent sale might temper enthusiasm.
• Management: The transactions highlight the executive's personal financial management and adherence to compliance protocols.

Next Steps

• The reporting person may continue to execute transactions under the Rule 10b5-1 trading plan.
• The company may receive written requests for detailed transaction information as noted in the footnotes.

Key Dates

Recommendation

The filing reports routine insider transactions under a 10b5-1 plan. While the sale of shares by a key executive can be a short-term negative signal, the structured nature of the plan mitigates concerns about opportunistic selling. Without additional financial performance data or strategic updates, a 'hold' recommendation is prudent, suggesting investors monitor future filings and company performance.

Keywords

SOPHiA GENETICS SA, Form 4, Insider Trading, Rule 10b5-1, Stock Options, Share Sales, Executive Chairman, Beneficial Ownership, SEC Filing, Jurgi Camblong